Intellectual Property Challenges for the Modern Biotechnology Enterprise: An Overview
Requires Subscription or Fee PDF


intellectual property


The paper investigates the IP protection in the field of biotechnology among new innovators. Incompatibilities of the development process in modern biotechnology and the current IP systems are highlighted. Development process in biotechnology is notoriously slow, characterized by long delays in obtaining experimental data and marketing approvals. Initial development stages have been accelerated by the development in silico, by the global competition and accessibility of information. Thus, the most valuable part of the innovation (e.g., genetic sequence, protein structure) may be known years before the full experimental data. This significantly increases the risks of losing IP protection due to competing development, espionage, accidental disclosure, urging the premature patenting despite lack of resources to maintain global patents. Moreover, in biotechnology enterprise prohibitive costs of international patenting deplete the limited development resources and adversely affect both patenting and development. Costs are compounded by the increasing complexity of obtaining IP protection. Some of the complexities are recognized and underline multiple legislative interventions in establishing special regulations for biotechnology. The market also adjusted through practices such as evergreening. Unfortunately, legislative and market responses are not serving new innovators and may be contributing to the biotechnology patenting conundrums. The paper suggests that new legal innovation is needed in order to sustain healthy innovation in biotechnology and address the needs of new innovators. Several general and specific features for advancement of the legal protection of biotechnology are proposed for further research and discussion.
Requires Subscription or Fee PDF


Acs, Zoltan; Audretsch, David B. Innovation and Small Firms 19-24 (1990).

Audretsch, David B.; Keilbach, Max C.; Lehmann, Erik E., Entrepreneurship and Economic Growth (2006).

Bilir, Kamran L. Patent Laws, Product Lifecycle Lengths, and Multinational Activity (2013).

Bird, Robert C., Defending Intellectual Property Rights in the BRIC Economies. American Business Law Journal (2006), 43: 317–363. doi: 10.1111/j.1744-1714.2006.00019.x

Block, Fred; Keller, Matthew R. Where Do Innovations Come From? Transformations in the U.S. National Innovation System, 1970-2006 (2008).

Cote Timothy R. Coté, Kui Xu, Anne R. Pariser. Accelerating orphan drug development Nature Reviews Drug Discovery 9, 901-902 (December 2010) | doi:10.1038/nrd3340

Cychosz, Allison. The Effectiveness of International Enforcement of Intellectual Property Rights. 37 J. Marshall L. Rev. 985 (2003-2004)

Drahos, P.; Mayne, R. Global intellectual property rights: knowledge, access and development (2002).

Dutfield, Graham. Intellectual Property Rights and the Life Science Industries: Past, Present and Future (2009). P. 196-205.

Kantarjian, Hagop, et al. The price of drugs for chronic myeloid leukemia (CML); A reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts, Blood. 2013 May 30;121(22):4439-42. PMID 23620577

Foray, Dominique, Intellectual property and innovation in the knowledge-based economy. Les Cahiers de l'Innovation (2000).

Frietsch, Rainer; Neuhäusler, Peter; Rothengatter, Oliver. SME Patenting – An Empirical Analysis in Nine Countries. Fraunhofer ISI Discussion Papers Innovation Systems and Policy Analysis No. 36, 2013. Available at:

Holzera, Adrian; Ondrusb, Jan, Mobile application market: A developer’s perspective. Telematics and Informatics, Volume 28, Issue 1, February 2011, P. 22–31

Kayser, Oliver; Warzecha, eds. Pharmaceutical biotechnology: drug discovery and clinical applications. John Wiley & Sons, 2012. P. 119-121.

Kingston, William, Enforcing Small Firms’ Patent Rights (2000).

Kneller, Robert, The importance of new companies for drug discovery: origins of a decade of new drugs. Nature Reviews Drug Discovery 9, 867-882 (November 2010)

Kravets, Leonid, Do Patents Really Matter To Startups? New Data Reveals Shifting Habits (2012)

Lanjouw, Jean O.; Schankerman, Mark. Protecting Intellectual Property Rights: Are Small Firms Handicapped? Journal of Law and Economics, Vol. 47, No. 1 (April 2004), pp. 45-74

May, C.; Sell, S.K. Intellectual property rights: a critical history (2006) 20-23.

Mitchell, John C., The Economic Failure of the patent system (2008).

Naughton, John. From Gutenberg to Zuckerberg: Disruptive Innovation in the Age of the Internet: Disruptive Innovation in the Age of the Internet (2014).

PWC (2014).

Rai, Arti; Boyle, James, Synthetic Biology: Caught between Property Rights, the Public Domain, and the Commons (2007). PLoS Biol 5(3): e58. doi:10.1371/journal.pbio.0050058

Shiva, Vandana. Protect of Plunder? Understanding Intellectual Property Rights (2001).

Sichelman, Ted M., Startups & the Patent System: A Narrative in Halbert, Deborah; Gallagher, William, eds. Law & Society Perspectives in Intellectual Property (2014) (forthcoming).

Smith, Donna. Copyright Protection for Intellectual Property Rights to Recombinant Deoxyribonucleic Acid: A Proposal, 19 St. Mary's L.J. 1083 (1987-1988).

Ståhl, Patrik L., and Joakim Lundeberg. "Toward the single-hour high-quality genome." Annual review of biochemistry 81 (2012): 359-378.

Stangler, Dane; Litan, Robert E., Where Will the Jobs Come From? Kauffman Foundation Research Series: Firm Formation and Economic Growth, Nov. 2009.

Vernaz, Nathalie; Haller, Guy; Girardin, Francois; Huttner, Benedikt; Combescure, Christophe, et al., Patented Drug Extension Strategies on Healthcare Spending: A Cost-Evaluation Analysis (2013). PLoS Med 10(6): e1001460. doi: 10.1371/journal.pmed.1001460

Unless specified by prior arrangement, the author agrees to the following terms and assurances:

  1. For myself and on behalf of the other authors listed on this work, I assign to thinkBiotech LLC the copyright* in the contribution for the full term throughout the world.
  2. I/we further give to the following assurances
    1. I am the sole author of the contribution, or, if not, I have the written authority of the other authors to transfer the copyright* to thinkBiotech LLC and give these warranties;
    2. I and (where appropriate) the other authors are entitled to transfer the copyright to thinkBiotech LLC and no one else would be entitled to prevent us from publishing the contribution;
    3. To the best of my/our knowledge, all the facts in the contribution are true and accurate;
    4. The content of the contribution is entirely original to me (and where appropriate to the other authors) or, if not, the written permission of the owner of the copyright in any material copied from elsewhere has been obtained for all media (all such permissions to be attached to the contribution as supplementary files);
    5. Nothing in the contribution is obscene or libellous;
    6. Nothing in the contribution infringes any duty of confidentiality which I/or the other authors may owe to anyone else.
    7. I and/or the other authors have obtained the appropriate clearances from my/our employer(s) or other concerned institution(s).
* Works by US government employees prepared as part of official duties are in the public domain and the authors are therefore exempt from copyright assignment.